Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1796280 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $11.28Day −5.29%Mkt cap $1.2B1Y +2.2%Off 52W high −24.4%Vol (1Y) 82.3%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,360 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest21.3% of sh out |
| Days to cover13.5d |
| 13F net flow (QoQ)−2.84% |
| Top-10 13F concentration44.7% |
| Next report (est.)2026-08-05 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$135.2M |
| ROE−41.3% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+37.9% |
| 1Y+2.2% |
| 3Y+34.9% |
| 5Y−34.5% |
| Since incept. (ann.)−19.1% |
Total return through 2026-07-29 · series begins 2021-02-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)82.3% |
| Ann. volatility (3Y)80.1% |
| Sharpe (1Y)0.45 |
| Sharpe (3Y)0.54 |
| Max drawdown (1Y)−48.1% |
| Max drawdown (3Y)−73.5% |
| Beta (3Y vs SPY)1.94 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Nextech Invest, Ltd. | 7.2M | $91M | 6.92% | +0.0% |
| EcoR1 Capital, LLC | 6.7M | $85M | 6.50% | +0.0% |
| BlackRock, Inc. | 6.0M | $76M | 5.78% | +1.9% |
| VIKING GLOBAL INVESTORS LP | 5.8M | $74M | 5.63% | −11.4% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 5.4M | $68M | 5.20% | +63.5% |
| SR One Capital Management, LP | 4.5M | $58M | 4.36% | +0.0% |
| Pfizer Inc | 4.8M | $58M | 4.62% | −11.1% |
| ALKEON CAPITAL MANAGEMENT LLC | 4.5M | $57M | 4.35% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 115.3% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 22,009,149 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-04 | −$0.34 | — | — | — |
| 2025-09-30 | 2025-11-13 | −$0.33 | — | — | — |
| 2025-06-30 | 2025-08-12 | −$0.47 | — | — | — |
| 2025-03-31 | 2025-05-05 | −$0.42 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-05 is ESTIMATED from filing cadence (median gap 93d) — not company-confirmed.
